Pityriasis versicolor

Journal of the European Academy of Dermatology and Venereology

Volumn 16, Issue 1, 2002, Pages 19-33

  Gupta, A K ^a   Bluhm, R ^a   Summerbell, R ^a  

^a NONE   (Canada)

Author keywords

Fungus; Malassezia; Pityriasis; Review; Tinea; Versicolor

Indexed keywords

ANTIFUNGAL AGENT; BENZOYL PEROXIDE; BIFONAZOLE; CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POVIDONE IODINE; PROPYLENE GLYCOL; PYRITHIONE ZINC; PYRROLE DERIVATIVE; RETINOIC ACID; SALICYLIC ACID; SELENIUM SULFIDE; SERTACONAZOLE; SHAMPOO; SULCONAZOLE; SULFUR; TERBINAFINE; TIOCONAZOLE; TOLCICLATE; WHITFIELD OINTMENT;

CLINICAL FEATURE; CONTROLLED STUDY; CREAM; DERMATOMYCOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HISTOLOGY; HUMAN; LOTION; MALASSEZIA; MICROSCOPY; MYCELIUM; PRIORITY JOURNAL; REVIEW; SKIN INFLAMMATION; TAXONOMY; TINEA VERSICOLOR; ULTRAVIOLET RADIATION; YEAST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; HUMANS; MALASSEZIA; RANDOMIZED CONTROLLED TRIALS; TINEA VERSICOLOR;

EID: 0036192080     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2002.00378.x     Document Type: Review

References (220)

1. Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis
2. Pityrosporum sabouraud
3. Lipophilic yeastlike organisms associated with tinea versicolor
4. Experimental infections in rabbits and humans with Pityrosporum orbuiculare and P. ovale
5. Pityriasis versicolor due to Malassezia ovalis
6. Tinea versicolor and Pityrosporum orbiculare: Mycological investigations, experimental infections and epidemiological surveys
7. Age incidence of Pityrosporum orbiculare on human skin
8. Pityriasis versicolor: Unicity or duality?
9. Polymorphism of Malassezia furfur
10. Studies of the genus Pityrosporum in submerged culture
11. Analysis of the lymphocyte transformation response to Pityrosporum orbiculare in patients with tinea versicolor
12. Loss of hair and dandruff
13. Immunological studies on Pityrosporum genus and Malassezia furfur
14. Antigenic similarities and differences in genus Pityrosporum
15. Exfoliative dermatitis in the Indian rhinoceros (Rhinoceros unicornis) with description of a new yeast species Pityrosporum pachydermatis
16. A new species of Malassezia
17. The genus Malassezia with description of four new species
18. Identification of Malassezia species: A practical approach
19. Molecular differentiation of seven Malassezia species
20. A single PCR-restriction endonuclease analysis for rapid identification of Malassezia species
21. Malassezia globosa as the causative agent of pityriasis versicolor
22. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects
23. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada
24. Synthesis of fluorochromes and pigments in Malassezia furfur by use of tryptophan as the single nitrogen source
25. Yeasts of the genus Malassezia: Taxonomic classification and significance in veterinary and clinical medicine
26. Changes in fungal ultrastructure after short-course ciclopiroxolamine therapy in pityriasis versicolor
27. In situ microbiology of the stratum corneum
28. The parasitic colonization of the horny layer in tinea versicolor
29. Electron microscopy of Malassezia furfur in tinea versicolor
30. The ultrastructure of tinea versicolor and Malassezia furfur
31. Tinea versicolor: Ultrastructural studies on hypopigmented and hyperpigmented skin
32. Pityriasis versicolor and Pityrosporum ovale. Morphogenetic and ultrastructural considerations
33. A novel cellular reaction caused by tinea versicolor: Extracellular glycogen deposits
34. Hypopigmentation in tinea versicolor: A histochemical and electronmicroscopic study
35. Hyperpigmented tinea versicolor
36. Decreased susceptibility of Malassezia furfur to UV light by synthesis of tryptophan derivatives
37. Tinea versicolor: Histologic and ultrastructural investigation of pigmentary changes
38. Tinea versicolor
39. Tinea versicolor: A light and electron microscopic study of hyperpigmented skin
40. The behavior of melanocytes in inflammation
41. An ultrastructure study of Pityrosporum orbiculare
42. Degenerative changes in fungi after itraconazole treatment
43. Scanning electron microscopic evaluation of tinea versicolor
44. Antibodies to Pityrosporum orbiculare in patients with tinea versicolor and controls of various ages
45. Seborrheic dermatitis and Pityrosporum (Malassezia) folliculties: Characterization of inflammatory cells and mediators in the skin by immunohistochemistry
46. The role of Pityrosporum ovale in sebborrheic dermatitis
47. Tinea versicolor hypopigmentation: Histochemical and therapeutic studies
48. Immunofluorescence studies in tinea versicolor
49. Comparison of antibody response in chronic mucocutaneous candidiasis and tinea versicolor
50. Humoral immunity in patients with tinea versicolor
51. Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls
52. Tinea versicolor: An update
53. Cell-mediated immunity to Pityrosporum orbiculae in tinea versicolor
54. Langerhans cell accumulation in chronic tinea pedis and pityriasis versicolor
55. Phenotypic characterization in situ of inflammatory cells in pityriasis (tinea) versicolor
56. The requirement of fatty acids by Pityrosporum ovale
57. Growth requirements and lipid metabolism of Pityrosporum orbiculare
58. Analyses of skin surface lipid in patients with microbially associated skin disease
59. Induction of hyphae in cultures of Pityrosporum by cholesterol and cholesterol esters
60. Superficial fungal infections
61. Tinea versicolor: Epidemiologic, clinical and therapeutic aspects
62. Tinea versicolor: Susceptibility factors and experimental infection in human beings
63. Tina versicolor and Pityrosporum orbiculare: A mycological investigation
64. Tinea versicolor
65. Common cutaneous disorders in athletes
66. Tinea versicolor of the face in black children in a temperate region
67. Tinea versicolor and body lotions
68. Tinea versicolor: Some new aspects on etiology, pathogenesis and treatment
69. Epidemiological survey of skin diseases in schoolchildren living in the Purus Valley (Acre State, Amazonia, Brazil)
70. Cutaneous fungal infection following renal transplantation: A case control study
71. An unusual case of tinea versicolor in an immunosuppressed patient
72. Management of common superficial fungal infections in patients with AIDS
73. HIV disease and Malassezia yeasts: A quantitative study of patients presenting with seborrhoeic dermatitis
74. Tinea versicolor and visceral leishmaniasis
75. An unusual presentation of tinea versicolor in an immunosuppressed patient
76. Common superficial fungal infections in patients with AIDS
77. Pityriasis versicolor confined to the radiation therapy field
78. Pityriasis versicolor associated with oral lithium therapy
79. Pityriasis versicolor: A clinical and mycological investigation
80. A clinical study of pityriasis versicolor in Madras
81. Tinea versicolor with regard to seborrheic dermatitis. An epidemiological investigation
82. Genetic susceptibility in pityriasis versicolor
83. Pityriasis versicolor
84. Pityriasis versicolor in the pediatric age
85. Pityriasis versicolor in children
86. Age of patients with pityriasis versicolor
87. Pediatric mycoses
88. Pityriasis versicolor in a 3-month old boy
89. Neonatal pityriasis versicolor
90. Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit
91. Malassezia furfur in dermatological patients and clinically normal persons
92. Versicolor in the aged
93. Pityriasis versicolor in the aged: A clinical investigation and epidemiological survey in 190 elderly hospitalized patients
94. Malassezia furfur: A fungus belonging to the physiological skin flora and its relevance in skin diseases
95. Pityrosporum foliculitis: A common acneiform condition of middle age
96. Pityrosporum folliculitis: A common disease of the young and middle-aged
97. Quantitative microbiology of the scalp in non-dandruff, dandruff and seborrhoeic dermatitis
98. Seborrhoeic dermatitis and Pityrosporum ovale: A cultural and immunological study
99. The response of seborrhoeic dermatitis to ketoconazole
100. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrheic dermatitis in adults
101. Rapid response of transient acantholytic dermatosis to selenium sulfide treatment for pityriasis versicolor
102. Papillomatose pigmentée innominée
103. Confluent and reticulated papillomatosis (Gougerot-Carteaud). An abnormal host reaction to Malassezia furfur
104. Confluent and reticulated papillomatosis responsive to selenium sulfide
105. Intravenous catheter-associated Malassezia furfur fungemia
106. Catheter-related infection in infants due to an unusual lipophilic yeast-Malassezia furfur
107. Malassezia fungemia in neonates and adults: Complication of hyperalimentation
108. The incidence of tinea versicolor in central Sweden
109. Epidemiology and clinical features of dermatomycoses and dermatophytoses
110. Pityriasis versicolor
111. The incidence of certain skin diseases in Western Samoa: A preliminary survey
112. Superficial fungal infections in the tropics
113. Itraconazole in the treatment of widespread tinea versicolor
114. Unusual locations of pityriasis versicolor with particular reference to scalp lesions
115. Tinea versicolor of the scalp
116. Tinea versicolor in immunosuppressed patients
117. Tinea versicolor of the face
118. Tinea versicolor of penis
119. Pityriasis versicolor of the penis
120. Pityriasis versicolor of the glans penis
121. Unilateral areolar and periareolar tinea versicolor
122. Inverse tinea versicolor
123. Tinea versicolor: Involvement of unusual sites
124. Tinea versicolor mimicking pityriasis rotunda
125. How I treat tinea versicolor
126. Diagnosis and treatment of tinea versicolor
127. Office dermatologic testing: The KOH preparation
128. A new stain for diphtheria bacilli
129. Albert's solution versus potassium hydroxide solution in the diagnosis of tinea versicolor
130. The distribution and ecology of Malassezia furfur and cutaneous bacteria on human skin
131. Experimental tinea versicolor in rabbits and humans with Pityrosporum orbiculare
132. An evaluation of O-T-C dandruff and seborrhea products
133. Selenium sulphide treatment of tinea versicolor
134. Double-blind efficacy study of selenium sulfide in tinea versicolor
135. Comparative clinical trial of bifonazole solution versus selenium sulfide shampoo in the treatment of pityriasis versicolor
136. Propylene glycol in the treatment of tinea versicolor
137. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis
138. Double-blind trial of 1% clotrimazole ream and Whitfield ointment in the treatment of pityriasis versicolor
139. Treatment of tinea versicolor with sulfur-salicylic shampoo
140. Editorial: Tinea versicolor treatment
141. The effect of povidone-iodine paint on fungal infection
142. Topical benzoyl peroxide for the treatment of tinea versicolor
143. Clinical efficacy studies of haloprogin, a new topical antimicrobial agent
144. An open trial of the effect of a zinc pyrithione shampoo in tinea versicolor
145. Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor
146. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate
147. The mode of antifungal action of tolnaftate
148. Multicentre clinical study with tolciclate in the local treatment of skin mycoses in 1083 patients
149. Tolciclate versus miconazole, a double-blind trial in patients with dermatomycosis
150. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%
151. Offene, auβereuropäische Studien zur Wirksamkeit und Vereträglichkeit von Ciclopiroxolamin bei Dermatomykosen
152. Topishe Andwendung einer 0.1%igen Ciclopiroxolamin-Lösung zur Behandlung der Pityriasis versicolor
153. Cambios estructurales producidos por el bifonazol 1% en hongos productores de micosis superficiales
154. Ultra-short topical treatment of pityriasis versicolor with 2.5% bifonazole cream
155. Bifonazole - A synopsis of clinical trials worldwide. Status and outlook
156. A comparison between two different regimens of monthly application with bifonazole spray 1% in pityriasis versicolor
157. Treatment of pityriasis versicolor with bifonazole shampoo: A randomized double-blind study
158. Short course bifonazole therapy in pityriasis versicolor
159. A single application of bifonazole 1% lotion in pityriasis versicolor
160. The topical therapy of pityriasis versicolor with clotrimazole
161. Clinical experience in the local treatment of dermatomycoses with clotrimazole
162. Superficial mycoses: Treatment with a new, broad-spectrum antifungal agent: 1% clotrimazole solution
163. Clinical evaluation of clotrimazole. A broad-spectrum antifungal agent
164. Double-blind comparison of clotrimazole with Whitfield's and nystatin ointments
165. Tinea versicolor treated with fluconazole shampoo
166. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor
167. Ketoconazole 2% shampoo in the treatment of tinea versicolor: A multicenter, randomized, double-blind, placebo-controlled study
168. Ketoconazole gel moussant à 2% dans le traitement du pityriasis versicolor (à propose de 60 cas)
169. Treatment of dermatomycoses with topical tioconazole and miconazole
170. Econazole 1% in the treatment of pityriasis versicolor in Zambia
171. A new treatment for tinea versicolor using econazole nitrate 1.0 percent cream once a day
172. Econazole 1% hampoo versus selenium in the treatment of tinea versicolor: A single-blind, randomized clinical study
173. Therapeutic efficacy and safety of the new antimycotic sertaconazole in the treatment of pityriasis versicolor
174. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor: A double-blind, multicenter study
175. A clinical and mycological assessment of tioconazole solution in the treatment of superficial dermatomycoses
176. Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor
177. Topical griseofulvin in tinea versicolor: A double-blind study
178. Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase
179. Tinea versicolor treated with terbinafine 1% solution
180. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: A placebo-controlled study
181. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor
182. Pityriasis versicolor: Clinical experience with Lamisil® cream and Lamisil® DermGel
183. Clinical efficacy and tolerability of terbinafine (Lamisil) - A new topical and systemic fungicidal drug for treatment of dermatomycoses
184. Systemic ketoconazole in tinea versicolor: A double-blind evaluation and 1-year follow-up
185. The successful treatment of pityriasis versicolor by systemic ketoconazole
186. 10-Tage-Therapie der Pityriasis versicolor mit Ketoconazole
187. Short course ketoconazole therapy in pityriasis versicolor
188. Comparison of single dose 400mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor
189. Systemic ketoconazole in the treatment of tinea versicolor
190. Pityriasis versicolor with ketoconazole
191. Pityriasis versicolor with ketoconazole
192. Tinea versicolor: Treatment and prophylaxis with ketoconazole
193. The use of intermittent itraconazole therapy for superficial mycotic infections: A review and update on the 'one week' approach
194. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor
195. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection
196. Treatment of pityriasis versicolor with itraconazole: A double-blind placebo controlled study
197. Itraconazole in tinea versicolor: A review
198. Treatment of dermatophytoses and pityriasis versicolor with itraconazole
199. Itraconazole therapy in pityriasis versicolor
200. Itraconazole in pityriasis versicolor: Ultrastructural changes in Malassezia furfur produced during treatment
201. Treatment of pityriasis versicolor with itraconazole
202. Itraconazole in pityriasis versicolor
203. Pityriasis versicolor: Efficacy of two five-day regimens of itraconazole
204. Itraconazole, a new orally active antifungal, in the treatment of pityriasis versicolor
205. Itraconazole: A new oral antimycotic for the treatment of pityriasis versicolor. Comparative clinical study of two treatment regimens
206. Oral itraconazole in the treatment of pityriasis versicolor: A comparison of two different dosage regimens
207. Itraconazole in the treatment of pityriasis versicolor: Results obtained in 30 patients
208. Itraconazole in the treatment of pityriasis versicolor: Comparison between 5 and 7 days of treatment
209. Fluconazole in the treatment of tinea versicolor
210. Treatment of pityriasis versicolor with a single dose of fluconazole
211. Oral fluconazole in the treatment of pityriasis versicolor
212. Itraconazole versus ketoconazole in the treatment of tinea versicolor
213. Fluconazole versus itraconazole in the treatment of tinea versicolor
214. Fluconazole vs. itraconazole in the treatment of tinea versicolor
215. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor
216. Tinea versicolor: Treatment and prophylaxis with ketoconazole
217. The efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor